SavedAdd your journal

Journals / Psikiyatride Güncel Yaklaşımlar / 2013 / Cilt: 5 - Sayı: 2

Pharmacological Treatment of Tourette Disorder

Tourette Bozukluğunda İlaç Tedavisi

Hande Ayraler Taner
Esra Güney
Yasemen Taner
Pages
246–259
Publication Date
2013-06-01
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In addition there are contradictory findings regarding the use of dopamine agonists, tetrabenazine, topiramate, levatirasetame, and delta-9-tetrahydrocannabinol in these patients.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Tourette disorder is a chronic neuropsychiatric disorder characterized by vocal and motor tics.
📊
Key Findings & Data:Primarily alpha 2 receptor agonists and antipsychotic drugs have been used in the treatment of Tourette disorder.
💡
Conclusion & Impact:In addition there are contradictory findings regarding the use of dopamine agonists, tetrabenazine, topiramate, levatirasetame, and delta-9-tetrahydrocannabinol in these patients.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Tourette Bozukluğu · tikler · antipsikotik ilaçlar.

Abstract

Tourette disorder is a chronic neuropsychiatric disorder characterized by vocal and motor tics. The course of the disorder shows waxing and vaning pattern and symptoms adversely affect patients' quality of life. Patients use psychopharmacologic agents for long periods to control their symptoms during which they also struggle with drug related side effects. Clinicians face serious difficulties in controlling symptoms with psychopharmacological agents. Primarily alpha 2 receptor agonists and antipsychotic drugs have been used in the treatment of Tourette disorder. Risperidone and aripiprazole are the most commonly used new generation antipsychotics in the treatment. In addition there are contradictory findings regarding the use of dopamine agonists, tetrabenazine, topiramate, levatirasetame, and delta-9-tetrahydrocannabinol in these patients.

Özet

Tourette bozukluğu motor ve vokal tiklerle karakterize kronik bir nöropsikiyatrik bozukluktur. Hastalığın seyrinde belirtilerde zaman zaman düzelmeler ve alevlenmeler görülebilmekte ve belirtiler hastaların yaşam kalitesini azaltmaktadır. Hastalar belirtilerinin tedavisi için uzun süre ilaç tedavisi almak zorunda kalmakta ve bunun yanı sıra pek çok ilaç yan etkisi ile karşılaşmaktadırlar. Tourette bozukluğu belirtilerinin farmakoterapi ile kontrolü kimi olgularda klinisyenleri ciddi bir şekilde zorlamaktadır. Tourette bozukluğu tedavisinde en sık alfa 2 reseptör agonistleri ve antipsikotik ilaçlar kullanılmaktadır. Tourette bozukluğu tedavisinde en sık kullanılan yeni nesil antipsikotikler risperidon ve aripiprazoldür. Bunun yanı sıra çelişkili sonuçları olan dopamin agonistleri, tetrabenazin, topiramat, levatirasetam ve delta-9-tetrahidrokannabinol ile yapılan yeni çalışmalar da mevcuttur.

🔖

Cite This Article

Taner, H. A., Güney, E., Taner, Y. (2013). Pharmacological Treatment of Tourette Disorder. Psikiyatride Güncel Yaklaşımlar, Cilt: 5 - Sayı: 2, 246–259. https://ajindex.com/articles/230257

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Bloch MH, Leckman JF. Tic disorders. In Lewis’s Child and Adolescent Psychiatry: A Comprensive Textbook, 4th ed. (Eds A Martin, FR Volkmar):569-583.
  2. Philadelphia, Lippincott Williams Wilkins, 2007.
  3. McNaught K St.P, Mink JW. Advances in understanding and treatment of Tourette syndrome. Nat Rev Neurol 2001; 7:667-676. American Psychiatric Association. Diagnostic and statistical manual of mental disorders (4th ed., text rev.). Washington DC, American Psychiatric Association, 2000.
  4. Carter AS, Pauls DL, Leckman JF, Cohen DJ. A prospective longitudinal study of Gilles de la Tourette's syndrome. J Am Acad Child Adolesc Psychiatry 1994; 33:377 Jankovic J. Tourette's syndrome. N Engl J Med 2001; 345:1184-1192. Robertson MM. The Gilles de la Tourette Syndrome: the current status. Arch Dis Child Educ Pract Ed 2012; 97:166-175. Cheung MY,Shahed C, Jankovic J. Malignant Tourette syndrome. Mov Disord 2007; 22:1743-1750.
  5. Hyde TM, Aaronson BA, Randolph C, Rickler KC, Weinberger DR. Relationship of birth weight to the phenotypic expression of Gilles de la Tourette's syndrome in monozygotic twins. Neurology 1992; 42:652-658.
  6. Price RA, Kidd KK, Cohen DJ, Pauls DL, Leckman JF. A twin study of Tourette syndrome. Arch Gen Psychiatry 1985; 42:815-820.
  7. Braun AR, Stoetter B, Randolph C, Hsiao JK, Vladar K, Gernert J et al. The functional neuroanatomy of Tourette's syndrome: an FDG-PET study. I: regional changes in cerebral glucose metabolism differentiating patients and controls. Neuropsychopharmacology 1993; 9:277-291.
  8. Braun AR, Randolph C, Stoetter B, Mohr E, Cox C, Vladar K et al.The functional neuroanatomy of Tourette's syndrome: an FDG-PET study. II: relationships between regional cerebral metabolism and associated behavioral and cognitive features of the illness, Neuropsychopharmacology 1995; 13:151-168.
  9. Albin RL, Koeppe RA, Bohnen NI, Nichols TE,Meyer P,Wernette K et al. Increased ventral striatal monoaminergic innervation in Tourette syndrome Neurology 2003; 61:310-315. Semerci B. Tik Bozuklukları. In Çocuk ve Ergen Ruh Sağlığı ve Hastalıkları, 1.baskı (Eds A Aysev, Y Taner):603-613.
  10. İstanbul, Golden Print, 2007.
  11. Hallett JJ, Harling-Berg CJ, Knopf PM, Stopa EG, Kiessling LS. Anti-striatal antibodies in Tourette syndrome cause neuronal dysfunction. J Neuroimmunol 2000; 111:195-202. Tourette Syndrome Study Group.treatment of ADHD in children with tics: a randomized controlled trial. Neurology 2002; 58:527-536.
  12. Roessner V, Plessen KJ, Rothenberger A, Ludolph AG, Rizzo R, Skov